share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/09/27 13:05

Moomoo AI 已提取核心訊息

TransCode Therapeutics received a third deficiency notice from Nasdaq on September 23, 2024, citing violation of shareholder approval requirements. The notice concerns a July 22 offering of 10 million shares at $0.30 per share, representing 137% of pre-transaction shares at a 62% discount to the minimum price, without obtaining shareholder approval.This follows two previous deficiency notices from August 2024: one for failing to maintain the $1.00 minimum bid price requirement, and another for falling below the $2.5 million minimum stockholders' equity requirement. The company is not eligible for the standard 180-day compliance period due to two reverse stock splits in the past two years.The company has appealed the delisting determination and will present its case at a Nasdaq Hearings Panel on October 1, 2024. The delisting action has been temporarily stayed pending the Panel's final decision, though there is no assurance that TransCode will regain compliance or maintain its Nasdaq listing.
TransCode Therapeutics received a third deficiency notice from Nasdaq on September 23, 2024, citing violation of shareholder approval requirements. The notice concerns a July 22 offering of 10 million shares at $0.30 per share, representing 137% of pre-transaction shares at a 62% discount to the minimum price, without obtaining shareholder approval.This follows two previous deficiency notices from August 2024: one for failing to maintain the $1.00 minimum bid price requirement, and another for falling below the $2.5 million minimum stockholders' equity requirement. The company is not eligible for the standard 180-day compliance period due to two reverse stock splits in the past two years.The company has appealed the delisting determination and will present its case at a Nasdaq Hearings Panel on October 1, 2024. The delisting action has been temporarily stayed pending the Panel's final decision, though there is no assurance that TransCode will regain compliance or maintain its Nasdaq listing.
TransCode Therapeutics於2024年9月23日收到了納斯達克發出的第三份缺陷通知,指出違反了股東批准要求。該通知涉及在7月22日以每股0.30美元發行1000萬股,代表交易前股份的137%,且價格比最低價低62%,未獲得股東批准。這之前在2024年8月收到了兩份缺陷通知:一份是未能維持1.00美元的最低買盤價格要求,另一份是低於250萬的最低股東權益要求。由於過去兩年進行了兩次拆股並股,公司不符合標準的180天合規期。公司已對退市決定提出上訴,並將在2024年10月1日的納斯達克聽證委員會上陳述其案情。退市行動已暫時中止,等待委員會的最終決定,但無法保證TransCode將恢復合規或保持其納斯達克上市。
TransCode Therapeutics於2024年9月23日收到了納斯達克發出的第三份缺陷通知,指出違反了股東批准要求。該通知涉及在7月22日以每股0.30美元發行1000萬股,代表交易前股份的137%,且價格比最低價低62%,未獲得股東批准。這之前在2024年8月收到了兩份缺陷通知:一份是未能維持1.00美元的最低買盤價格要求,另一份是低於250萬的最低股東權益要求。由於過去兩年進行了兩次拆股並股,公司不符合標準的180天合規期。公司已對退市決定提出上訴,並將在2024年10月1日的納斯達克聽證委員會上陳述其案情。退市行動已暫時中止,等待委員會的最終決定,但無法保證TransCode將恢復合規或保持其納斯達克上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息